Statins for the prevention of dementia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD003160.pub2PMID 19370582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• P3‐391: Statins for the treatment of dementia

  2010cited by this paper
• The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics

  2008cited by this paper
• Statins, incident Alzheimer disease, change in cognitive function, and neuropathology

  2008cited by this paper
• Reduced risk of incident AD with elective statin use in a clinical trial cohort.

  2008cited by this paper
• Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins

  2007cited by this paper
• Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease

  2007cited by this paper
• Association Between Apolipoprotein E4 and Cognitive Decline in Elderly Adults

  2007cited by this paper
• Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease

  2007cited by this paper
• Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments

  2006cited by this paper
• Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol‐Lowering Treatment (ADCLT) trial

  2006cited by this paper
• Lipid-lowering drugs

  2006cited by this paper
• High-dose atorvastatin after stroke or transient ischemic attack.

  2006cited by this paper
• Serum Cholesterol and Cognitive Performance in the Framingham Heart Study

  2005cited by this paper
• Statin use and the risk of incident dementia: the Cardiovascular Health Study.

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

  2005cited by this paper
• APOE genotype, cholesterol level, lipid-lowering treatment, and dementia

  2005cited by this paper
• Vascular factors in dementia: an overview.

  2004cited by this paper
• Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults.

  2004cited by this paper
• Serum cholesterol concentrations are associated with visuomotor speed in men: findings from the third National Health and Nutrition Examination Survey, 1988-1994.

  2004cited by this paper
• Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes.

  2004cited by this paper
• Statin therapy and risk of dementia in the elderly

  2004cited by this paper
• The Role of Cholesterol and Statins in Alzheimer's Disease

  2004cited by this paper
• Relation of plasma lipids to Alzheimer disease and vascular dementia.

  2004cited by this paper
• Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients.

  2004cited by this paper
• Association between Statin Use and Alzheimer’s Disease

  2004cited by this paper
• Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts

  2003cited by this paper
• Cognitive Impairment Associated with Atorvastatin and Simvastatin

  2003cited by this paper
• Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques.

  2003cited by this paper
• APP Processing Enzymes (Secretases) as Therapeutic Targets: Insights from the Use of Transgenics (Tgs) and Transfected Cells

  2003cited by this paper
• Donepezil in vascular dementia

  2003cited by this paper
• Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial

  2003cited by this paper
• Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature

  2003cited by this paper
• Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia

  2002cited by this paper
• Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

  2002cited by this paper
• New Possible Role of Statins in Age‐Related Diseases

  2002cited by this paper
• Use of Lipid‐Lowering Drugs in Older Adults With and Without Dementia: A Community‐Based Epidemiological Study

  2002cited by this paper
• Association between high‐density lipoprotein and cognitive impairment in the oldest old

  2002cited by this paper
• The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• Plasma antioxidant activity and vascular dementia.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Isoprenoids as mediators of the biological effects of statins.

  2002cited by this paper
• [Vascular dementia and systemic changes].

  2002cited by this paper
• The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment.

  2002cited by this paper
• Paraoxonase 1 Activity: A New Vascular Marker of Dementia?

  2002cited by this paper
• Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease

  2002cited by this paper
• Serum lipoprotein levels, statin use, and cognitive function in older women.

  2002cited by this paper
• HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species

  2001cited by this paper
• Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease

  2001cited by this paper
• High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock

  2001cited by this paper
• Statins for the prevention of Alzheimer's disease.

  2001cited by this paper
• CNS synaptogenesis promoted by glia-derived cholesterol.

  2001cited by this paper
• Cholesterol and Alzheimer’s disease

  2001cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

  2001cited by this paper
• Statins and the risk of dementia.

  2000cited by this paper
• Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?

  2000cited by this paper
• Effects of lovastatin on cognitive function and psychological well-being.

  2000cited by this paper
• Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

  2000cited by this paper
• Neuropathological Substrates of Dementia and Depression in Vascular Dementia, with a Particular Focus on Cases with Small Infarct Volumes

  2000cited by this paper
• Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model

  2000cited by this paper
• Type 2 diabetes mellitus, cognitive impairment and dementia

  1999cited by this paper
• Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles

  1999cited by this paper
• Cholesterol-dependent Generation of a Seeding Amyloid β-Protein in Cell Culture*

  1999cited by this paper
• The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.

  1999cited by this paper
• Removal of cholesterol from extrahepatic sources by oxidative mechanisms.

  1999cited by this paper
• Low-density lipoprotein cholesterol and the risk of dementia with stroke.

  1999cited by this paper
• Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

  1998cited by this paper
• Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

  1998cited by this paper
• Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis

  1998cited by this paper
• Status of Risk Factors for Vascular Dementia

  1998cited by this paper
• Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study.

  1998cited by this paper
• Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.

  1998cited by this paper
• Effect of Pharmacologic Lipid Lowering on Health‐Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study

  1997cited by this paper
• Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.

  1997cited by this paper
• Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

  1997cited by this paper
• Serum Cholesterol and Intellectual Performance

  1997cited by this paper
• Enhanced oxidizability of ubiquinol and α‐tocopherol during lovastatin treatment

  1997cited by this paper
• Neuropathological assessment of the lesions of significance in vascular dementia

  1997cited by this paper
• Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation.

  1996cited by this paper
• Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein.

  1996cited by this paper
• Subchronic Toxicity of Atorvastatin, a Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, in Beagle Dogs

  1996cited by this paper
• Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain.

  1995cited by this paper
• High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules.

  1995cited by this paper
• Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease

  1995cited by this paper
• Is Alzheimer's disease an apolipoprotein E amyloidosis?

  1995cited by this paper
• Cerebral white matter lesions, vascular risk factors, and cognitive function in a population‐based study

  1994cited by this paper
• Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study.

  1994cited by this paper
• Low Levels of Serum Apolipoprotein AI and AII in Senile Dementia

  1994cited by this paper
• Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study.

  1994cited by this paper
• Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

  1993cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Apolipoprotein E alleles and hyperlipoproteinemia in Japan

  1988cited by this paper
• Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

  1988cited by this paper
• High-density lipoprotein cholesterol in differential diagnosis of senile dementia.

  1985cited by this paper

• Relationships between heritable dementia risk factors, cardiovascular risk factors in young adulthood, and midlife neuropsychological outcomes

  2026cites this paper
• Alzheimer's disease in patients prescribed statins: A real-world data analysis of U.S. patient health records.

  2026cites this paper
• Statin deprescribing: a comprehensive review and development of a clinical algorithm for optimal patient management.

  2026cites this paper
• “The association of cardiometabolic diseases and related medications with cognitive performance: a cross-sectional observational study from Central Poland”

  2025cites this paper
• Exploring the relationship between lipid-lowering drug target genes and sensorineural hearing loss by Mendelian randomization

  2025cites this paper
• Searching for responders to multidomain dementia prevention in late life: A pooled analysis of individual participant data from the MAPT and preDIVA trials

  2025cites this paper
• STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER): study protocol for a randomised, open label clinical trial in patients with persistent neurological symptoms after COVID-19 infection

  2025cites this paper
• The Impact of Cognitive Impairment on Cardiovascular Disease.

  2025cites this paper
• Neuro-cognitive profile of adult statin users at a large tertiary care hospital in Delhi, India

  2025cites this paper
• PACAP: A promising disease-modifying target for Alzheimer's disease.

  2025cites this paper
• Lipidome disruption in Alzheimer’s disease brain: detection, pathological mechanisms, and therapeutic implications

  2025cites this paper
• Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia

  2025cites this paper
• Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions

  2025cites this paper
• The longitudinal association between dyslipidemia and cognitive trajectory

  2025cites this paper
• Medical risk factors, ApoE haplotype, and Alzheimer’s disease: a large-scale analysis

  2025cites this paper
• Cholesterol‐lowering drug targets reduce risk of dementia: Mendelian randomization and meta‐analyses of 1 million individuals

  2025cites this paper
• Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis: A cross-sectional study from the Swedish registry for cognitive/dementia disorders

  2025cites this paper
• Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis

  2025cites this paper
• Recent Advancements in Neuroimaging‐Based Alzheimer's Disease Prediction Using Deep Learning Approaches in e‐Health: A Systematic Review

  2025cites this paper
• Hypercholesterolemia and the Increased Risk of Vascular Dementia: a Cholesterol Perspective

  2024cites this paper
• Adverse Lipid Profiles Are Associated With Lower Dementia Risk in Older People.

  2024cites this paper
• Therapeutic Challenges Derived from the Interaction Among Apolipoprotein E, Cholesterol, and Amyloid in Alzheimer’s Disease

  2024cites this paper
• The role of statins in amyotrophic lateral sclerosis: protective or not?

  2024cites this paper
• Dementia Prevention and Treatment: A Narrative Review.

  2024cites this paper
• Causal cardiovascular risk factors for dementia: insights from observational and genetic studies

  2024cites this paper
• Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision

  2024cites this paper
• Use of common cardiovascular disease drugs and risk of dementia: A case–control study in Swedish national register data

  2024cites this paper
• Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.

  2024cites this paper
• Simvastatin, Its Antimicrobial Activity and Its Prevention of Alzheimer’s Disease

  2024cites this paper
• Mouse PAW: reverse-translating the FINGER multimodal lifestyle intervention enhances synaptic plasticity and cognition in adult wild type female mice

  2024cites this paper
• Consideration of T-Cell Profile in the Examination of Statin Efficacy in Inflammatory Diseases, Neurodegeneration, and Neurocognitive Performance

  2024cites this paper
• Current and Future Treatments of Vascular Cognitive Impairment

  2024influential citation
• Predicting Alzheimer's disease from cognitive footprints in mid and late life: How much can register data and machine learning help?

  2024cites this paper
• Prävention demenzieller Erkrankungen

  2024cites this paper
• Predicting mid- and late-life dementia risk in primary care: A prognostic study from a national health screening cohort.

  2024cites this paper
• Deep Learning Based Alzheimer Disease Diagnosis: A Comprehensive Review

  2024cites this paper
• Somatic comorbidity and the progression of cognitive impairment

  2023cites this paper
• Statin use moderates APOE's and CRP's associations with dementia and is associated with lesser dementia severity in ε4 carriers

  2023cites this paper
• Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients.

  2023cites this paper
• Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health

  2023cites this paper
• Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association

  2023cites this paper
• Early Signal Detection: Data Mining of Mental Disorders with Statins

  2023cites this paper
• Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes

  2023cites this paper
• Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults

  2023cites this paper
• Statins modify the response of chicks to challenges with xylazine-ketamine and carbaryl

  2023cites this paper
• Recomendations for the prevention of adverse drug reactions in older adults with dementia

  2023cites this paper
• Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study

  2023cites this paper
• Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation

  2023cites this paper
• New horizons in cognitive and functional impairment as a consequence of cerebral small vessel disease

  2023cites this paper
• Associations of dietary cholesterol and fat, blood lipids, and risk for dementia in older women vary by APOE genotype

  2023cites this paper
• Does statin use reduce the risk of dementia?

  2023cites this paper
• What is the impact of ongoing statin use on cognitive decline and dementia progression in older adults with mild-moderate Alzheimer disease?

  2023cites this paper
• Change in lipids before onset of dementia, coronary heart disease, and mortality: A 28‐year follow‐up Whitehall II prospective cohort study

  2023cites this paper
• Reexamining the Causes and Effects of Cholesterol Deposition in the Brains of Patients with Alzheimer’s Disease

  2023cites this paper
• The factors associated with cognitive function among community-dwelling older adults in Taiwan

  2023cites this paper
• The relationship between midlife dyslipidemia and lifetime incidence of dementia: A systematic review and meta‐analysis of cohort studies

  2023cites this paper
• Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.

  2023cites this paper
• Acute ACAT1/SOAT1 Blockade Increases MAM Cholesterol and Strengthens ER-Mitochondria Connectivity

  2023cites this paper
• Sarcopenia and diabetes-induced dementia risk

  2023cites this paper
• Differential effects of statins on plasma and brain cholinesterase activities in chicks

  2023influential citation
• Prävention demenzieller Erkrankungen

  2023cites this paper
• Adiposity impacts cognitive function in Asian populations: an epidemiological and Mendelian Randomization study

  2023cites this paper
• Title: A multi-omics approach identifies a blood-based miRNA signature of cognitive decline in two large observational trials Running title: Blood-microRNA as biomarker of cognitive decline

  2022cites this paper
• Effect of Controlling the Cardiovascular Risk Factors on the Cognitive Decline Prevention in the Elderly: A Systematic Review

  2022cites this paper
• The Role of High-Density Lipoprotein in Lowering Risk of Dementia in the Elderly: A Review

  2022cites this paper
• Statins in Alzheimer’s disease (AD)

  2022cites this paper
• Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review

  2022cites this paper
• Association of cognitive function, depression, and quality of sleep with statins among oldest-old individuals

  2022cites this paper
• Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

  2022cites this paper
• Statin use is associated with lower risk of dementia in stroke patients: a community-based cohort study with inverse probability weighted marginal structural model analysis

  2022cites this paper
• Association of Familial Hypercholesterolemia and Statin Use With Risk of Dementia in Norway

  2022cites this paper
• Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise

  2022cites this paper
• Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance

  2022cites this paper
• Primary prevention statin therapy in older adults

  2022cites this paper
• Cardiovascular factors in dementia.

  2022cites this paper
• Frequency and Underlying Pathology of Pure Vascular Cognitive Impairment.

  2022cites this paper
• PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?

  2022cites this paper
• Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

  2022influential citation
• Trials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes

  2022cites this paper
• Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

  2022cites this paper
• Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease

  2022cites this paper
• A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease

  2021cites this paper
• Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies

  2021cites this paper
• Exploring the Genetic Associations Between the Use of Statins and Alzheimer's Disease

  2021cites this paper
• HIGH-SENSITIVITY CARDIAC TROPONIN T FOR THE DETECTION OF MYOCARDIAL INJURY AND RISK STRATIFICATION IN COVID-19

  2021cites this paper
• Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinson’s Disease

  2021cites this paper
• Promoting Successful Cognitive Aging: A Ten-Year Update

  2021cites this paper
• Adherence to Statins Use and Risk of Dementia among Patients with Diabetes and Comorbid Hyperlipidemia

  2021cites this paper
• Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective

  2021cites this paper
• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.

  2021cites this paper
• Environmental Risk Factors for Progressive Supranuclear Palsy

  2021cites this paper
• Plasma phosphatidylcholines and vitamin B12/folate levels are possible prognostic biomarkers for progression of Alzheimer's disease.

  2021cites this paper
• Effects of statins on mitochondrial pathways

  2021cites this paper
• Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies.

  2021cites this paper
• Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in‐depth exploration of seven established risk factors

  2021cites this paper
• Total Cholesterol and APOE-Related Risk for Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging Initiative

  2021cites this paper
• A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association.

  2021cites this paper
• Evaluation of High Cholesterol and Risk of Dementia and Cognitive Decline in Older Adults Using Individual Patient Meta-Analysis

  2021cites this paper
• The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?

  2021cites this paper
• An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia

  2021cites this paper